Skip to Main Content

Edwin Alexander Alvarez


Gynecologic cancer surgeon

Dr. Edwin Alexander Alvarez is a gynecologic oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center. He focuses on the surgical and medical treatment of ovarian cancer, cervical cancer, endometrial cancer and other cancers of the female reproductive system. He performs traditional, complicated and minimally invasive gynecologic surgeries.

UCSF recruited Alvarez to serve as director of clinical trials for the Division of Gynecologic Oncology. He is involved with NRG Oncology, a cooperative research group for cancer clinical trials sponsored by the National Cancer Institute. Before coming to UCSF, he directed chemotherapy services for gynecologic cancers at the University of California, Davis.

In addition to caring for patients, Alvarez has a strong commitment to teaching medical students, residents and fellows.

  • Education

    UC San Diego School of Medicine, 2000

  • Residencies

    LAC-USC Medical Center, Obstetrics and Gynecology, 2004

  • Fellowships

    University of Miami School of Medicine, Gynecologic Oncology, 2007

  • Board Certifications

    Obstetrics and Gynecology, American Board of Obstetrics and Gynecology

    Gynecologic Oncology, American Board of Obstetrics and Gynecology

  • Academic Title

    Clinical Professor

  • Languages


Where I see patients (1)

    My reviews


    Overall Experience
    264 Ratings
    Explained things in a way that was easy to understand
    262 Ratings
    Did the doctor pay attention to your concerns
    260 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    257 Ratings
    Knew the important information about your medical history
    262 Ratings
    The provider showed respect for what you had to say
    260 Ratings
    The provider spent enough time with me
    259 Ratings
    Decorative Caduceus

    Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance ...

    Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression)


    Decorative Caduceus

    A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometr...

    Overall response rate for each biomarker cohort is defined as the proportion of patients achieving a complete (CR) or partial (PR) response on two consecutive occasions at least 4 weeks apart, as determined by the investigator fro...


    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.